Neutrophil Extracellular Trap Components Associate with Infarct Size, Ventricular Function, and Clinical Outcome in STEMI.
Ragnhild HelsethChristian SheteligGeir Øystein AndersenMiriam Sjåstad LangsethShanmuganathan LimalanathanTrine B OpstadHarald ArnesenPavel HoffmannJan EritslandIngebjørg SeljeflotPublished in: Mediators of inflammation (2019)
High day 1 dsDNA levels after STEMI were associated with myocardial infarct size, adverse left ventricular remodeling, and clinical outcome. Although the origin of dsDNA could be discussed, these observations indicate a potential role for dsDNA in acute myocardial ischemia. This trial is registered with S-08421d, 2008/10614 (Regional Committee for Medical Research Ethics in South-East Norway (2008)).
Keyphrases
- left ventricular
- acute myocardial infarction
- percutaneous coronary intervention
- hypertrophic cardiomyopathy
- st segment elevation myocardial infarction
- st elevation myocardial infarction
- cardiac resynchronization therapy
- heart failure
- liver failure
- aortic stenosis
- left atrial
- mitral valve
- public health
- healthcare
- study protocol
- phase iii
- respiratory failure
- coronary artery disease
- acute coronary syndrome
- randomized controlled trial
- atrial fibrillation
- adverse drug
- open label
- ejection fraction
- mechanical ventilation